Related Experiment Video

Updated: Aug 18, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.0K

Targeted Protein Degradation: Clinical Advances in the Field of Oncology

Abdelrahman K A A Salama1, Marija V Trkulja1, Emilio Casanova1

  • 1Department of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria.

International Journal of Molecular Sciences
|December 11, 2022
PubMed

Insights

Targeted protein degradation (TPD) offers a novel therapeutic approach to target disease-causing proteins. This review highlights recent TPD advances and their clinical potential in cancer treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted protein degradation (TPD) is an emerging therapeutic strategy.
  • It offers a unique approach to target proteins intractable by conventional methods.
  • The field has advanced significantly, with several TPD drugs entering clinical trials.

Purpose of the Study:

  • To provide an updated overview of recent advancements in TPD.
  • To discuss the clinical implications of TPD for cancer prevention and treatment.
  • To highlight the potential of TPD as a therapeutic modality.

Main Methods:

  • Literature review of recent studies in targeted protein degradation.
  • Analysis of clinical trial data for TPD drugs.
  • Discussion of emerging TPD technologies and strategies.

Main Results:

  • Multiple TPD drugs are now in clinical development.
  • TPD has shown promise in targeting previously undruggable proteins.
  • Recent advances have expanded the scope and applicability of TPD.

Conclusions:

  • TPD is a rapidly evolving field with significant therapeutic promise.
  • Continued research and development are expected to yield more TPD-based treatments.
  • TPD holds potential for transforming cancer therapy and prevention.
Keywords:
cancerclinical trialsdegrader moleculestargeted protein degradation

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Regulated Protein Degradation02:58

Regulated Protein Degradation

2.6K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K